资源描述:
《Nodal ratio of positive to excised nodes, but not number of positive lymph nodes is better to predict group to avoid chemotherap》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、OriginalArticleNodalratioofpositivetoexcisednodes,butnotnumberofpositivelymphnodesisbettertopredictgrouptoavoidchemotherapyamongpostmenopausalER‑positive,lymphnode‑positiveT1‑T2breastcancerpatientsX.Q.Jia,Q.Hong,ABSTRACTJ.Y.Cheng1,AimofStudy:Toidentifywhet
2、hernodalratio(NR)ofpositivetoexcisednodesissuperiortonumberofpositivelymphnodestoJ.W.Li,predictgrouptoavoidchemotherapyamongpostmenopausalER‑positive,lymphnode‑positive,T1‑T2breastcancerpatients.Y.J.Wang,M.Mo2,MaterialsandMethods:Postmenopausalestrogenrece
3、ptor(ER)‑positive,lymphnode‑positivepatientswhoreceivedendocrineZ.M.Shao,therapy(n=173)withcompletebaselinedatainourhospitalbetween2000and2006wereincluded.Thedisease‑freesurvival(DFS)Z.Z.Shen,wascompared.SurvivalanalysiswasperformedusingKaplan–Meiermethod.
4、CoxproportionalhazardmodelswereusedtoevaluateG.Y.LiutheprognosticvalueofchemotherapywithdifferentNRforDFS.P‑valueslessthan0.05wereregardedassignificant.Results:Themedianfollow‑upwas72months.Threeof13variablesanalyzedremainedsignificantlyprognosticforsurviv
5、alintheCoxDepartmentsofBreastSurgery,proportionalhazardsmodel.Theseincludedage(hazardratio(HR)=1.642,95%confidenceinterval(CI)=1.154‑2.337,P=0.006);1NuclearMedicine,histologicalgrade(HR=2.463,95%CI=1.389‑4.367,P=0.002);andNR(HR=2.280,95%CI=1.113‑4.671,P=0.
6、024).2Epidemiology,SchoolSubgroupanalysisbyNRstatusshowedthatinpatientswithNR≥0.20,chemotherapysignificantlyimprovesDFS(HR=0.360,ofPublicHealth,95%CI=0.195‑0.663,P=0.001);whileinpatientswithNR<0.20,chemotherapydidnotsignificantlyaffectDFS(HR=0.677,CancerCe
7、nterand95%CI=0.227‑2.107,P=0.493).RadiotherapyisanimportantfactorthatimprovesDFSinlymphnode‑positivepatients,soitCancerInstitute,ShanghaiMedicalisconsideredinallanalysis.College,FudanConclusion:ThisretrospectiveanalysisdemonstratesthatNRofpositivetoexcised
8、nodes,butnotnumberofpositivelymphnodesisUniversity,Shanghai,bettertopredictgrouptoavoidchemotherapyamongpostmenopausalER‑positive,lymphnode‑positiveT1‑T2breastcancerpatients.ChinaForcorrespondence:Dr.G.Y.Liu,